Home
Why Choose Fox Chase?
Patient Center
Learn About Cancer
Find a Doctor
Molecular Medicine
Prevention, Risk and Screening
 
Research at Fox Chase
Research Areas
Faculty
by Program
by Research
Faculty Summaries
Research Facilities
Technology Transfer
Postdoctoral Research Program
Graduate Student Programs
Pre-Graduate Research Programs
Talbot Research Library
Awards and Honors
Partner Hospitals
For Health Professionals
Giving and Volunteering
Mitchell R Smith, MD, PhD Mitchell R Smith, MD, PhD
Mitchell R Smith, MD, PhD
Professor

2011

  • Smith MR. Should there be a standard therapy for mantle cell lymphoma?. Future Oncol. 2011 Feb;7(2):227-37.
  • Carlson RW, Allred C, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Ljung BM, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Sachdev J, Smith ML, Somlo G, Ward JH, Wolff AC, Zellars R. Invasive Breast Cancer. Journal of the National Comprehensive Cancer Network. 2011 Feb;9(2):136-222.
Top

2010

  • Advani A, Coiffier B, Czuczman MS, Dreyling M, Foran J, Gine E, Gisselbrecht C, Ketterer N, Nasta S, Rohatiner A, Schmidt-Wolf IG, Schuler M, Sierra J, Smith MR, Verhoef G, Winter JN, Boni J, Vandendries E, Shapiro M, Fayad L. Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study. J Clin Oncol. 2010 Apr;28(12):2085-93.
  • Younes A, Vose JM, Zelenetz AD, Smith MR, Burris HA, Ansell SM, Klein J, Halpern W, Miceli R, Kumm E, Fox NL, Czuczman MS. A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma. Br J Cancer. 2010 Dec;103(12):1783-7.
  • Gitelson E, Al-Saleem T, Robu V, Millenson MM, Smith MR. Pediatric nodal marginal zone lymphoma may develop in the adult population. Leuk Lymphoma. 2010 Jan;51(1):89-94.
  • Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Ljung BM, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Smith ML, Som G, Topham NS, Ward JH, Winer EP, Wolff AC. Breast Cancer: Noninvasive and Special Situations. Journal of the National Comprehensive Cancer Network. 2010 Oct;8(10):1182-207.
  • Reyes VE, Al-Saleem T, Robu VG, Smith MR. Extranodal NK/T-cell lymphoma nasal type: Efficacy of pegaspargase. Report of two patients from the United Sates and review of literature. Leuk Res. 2010 Jan;34(1):E50-E54.
Top

2009

  • Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MR. Cardiovascular Mortality After Androgen Deprivation Therapy for Locally Advanced Prostate Cancer: RTOG 85-31. J Clin Oncol. 2009 Jan;27(1):92-9.
  • Bevers TB, Anderson BO, Bonaccio E, Buys S, Daly MB, Dempsey PJ, Farrar WB, Fleming I, Garber JE, Harris RE, Heerdt AS, Helvie M, Huff JG, Khakpour N, Khan SA, Krontiras H, Lyman G, Rafferty E, Shaw S, Smith ML, Tsangaris TN, Williams C, Yaneeklov T. NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. J Natl Compr Canc Netw. 2009 Nov;7(10):1060-96.
  • Borghaei H, Smith MR, Campbell KS. Immunotherapy of cancer. Eur J Pharmacol. 2009 Dec;625(1-3):41-54.
  • Johnson WM, Fayad LE, Coiffier B, Smith MD, Rohatiner A, Hess G, Kaufman JL, Verhoef G, Offner F, Hua S, Patel H, Vandendries ER, Dang NH. Safety and clinical Activity of the ANTI-CD22 Immunoconjugate Intozumab Ozogamicin (CMC-544) in combination with Rituximab in recurrent/refractory follicular lymphoma or diffuses large B-cell lymphoma. Haematologica-The Hematology Journal. 2009;94:165.
  • Gitelson E, Al-Saleem T, Smith MR. Review: lymphomatoid granulomatosis: challenges in diagnosis and treatment. Clin Adv Hematol Oncol. 2009 Jan;7(1):68-70.
  • Borghaei H, Smith MR, Campbell KS. Immunotherapy of cancer. Eur J Pharmacol. 2009 Dec 25;625(1-3):41-54.
  • Leong S, Cohen RB, Gustafson DL, Langer CJ, Camidge DR, Padavic K, Gore L, Smith M, Chow LQ, von Mehren M, O'Bryant C, Hariharan S, Diab S, Fox NL, Miceli R, Eckhardt SG. Mapatumumab, an Antibody Targeting TRAIL-R1, in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Malignancies: Results of a Phase I and Pharmacokinetic Study. J Clin Oncol. 2009 Sep;27(26):4413-21.
  • Stein R, Smith MR, Chen S, Zalath M, Goldenberg DM. Combining Milatuzumab with Bortezomib, Doxorubicin, or Dexamethasone Improves Responses in Multiple Myeloma Cell Lines. Clin Cancer Res. 2009 Apr;15(8):2808-17.
Top

2008

  • Shafer D, Wu H, Al-Saleem T, Reddy K, Borghaei H, Lessin S, Smith M. Cutaneous precursor B-cell lymphoblastic lymphoma in 2 adult patients: clinicopathologic and molecular cytogenetic studies with a review of the literature. Arch Dermatol. 2008 Sep;144(9):1155-62.
  • Carlson RW, Moench S, Hurria A, Balducci L, Burstein HJ, Goldstein LJ, Gradishar WJ, Hughes KS, Jahanzeb M, Lichtman SM, Marks LB, McClure JS, McCormick B, Nabell LM, Pierce LJ, Smith ML, Topham NS, Traina TA, Ward JH, Winer EP. NCCN Task Force Report: breast cancer in the older woman. J Natl Compr Canc Netw. 2008;6 Suppl 4:S1-S25; quiz S26-S27.
  • Pro B, Leber B, Smith M, Fayad L, Romaguera J, Hagemeister F, Rodriguez A, McLaughlin P, Samaniego F, Zwiebel J, Lopez A, Kwak L, Younes A. Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma. Br J Haematol. 2008 Nov;143(3):355-60.
  • Zelenetz AD, Advani RH, Byrd JC, Czuczman MS, Damon LE, Duvic M, Fayad L, Forero A, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kaminski MS, Kim YH, Lacasce AS, Nademanee A, Olsen EA, Porcu P, Press O, Prosnitz L, Smith MR, Sotomayor EM, Vose JM, Yahalom J, Yunus F, National Comprehensive Cancer N. Non-Hodgkin's lymphomas. J Natl Compr Canc Netw. 2008 Apr;6(4):356-421.
  • Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MR. Cardiovascular Mortality and Duration of Androgen Deprivation for Locally Advanced Prostate Cancer: Analysis of RTOG 92-02. Eur Urol. 2008 Oct;54(4):816-24.
  • Leonard JP, LaCasce A, Smith MR, Noy A, Yap JT, Van den Abbeele AD, Yu JQ, Chen-Kiang S, Ely SA, Vallabhajosula S, Chirieac LR, Larson SM, Shapiro GI, Schoder H. Cdk4/6 Inhibitor PD 0332991 Demonstrates Cell Cycle Inhibition Via FLT-PET Imaging and Tissue Analysis in Patients with Recurrent Mantle Cell Lymphoma. 2008;:104.
  • Wang HW, Cheng F, Wright K, Tao J, Smith M, Pinilla J, Dessureault S, Sebti S, Sotomayor EM. Targeting STAT3 Signaling to Augment the Immunogenicity of B-Cell Lymphomas. Blood Cells. 2008;112(11):263.
  • Smith MR. Mantle cell lymphoma: advances in biology and therapy. Curr Opin Hematol. 2008 Jul;15(4):415-21.
  • Smith MR. Antibodies and hematologic malignancies. Cancer J. 2008 May-Jun;14(3):184-90.
Top

2007

  • Shafer D, Smith MR, Litwin S, Li T, Borghaei H, Al-Saleem TI. Peripheral blood CD3(+)CD4(+) and CD3(-)CD56(+) cell counts and circulating lymphoma cells are significant predictors of overall survival in newly diagnosed follicular lymphoma. Blood. 2007 Nov;110(11):767A-768A.
  • Borghaei H, Smith M, Millenson M, Thibodeau L, Kamiensky N, Schilder RJ. Phase I trial of combination therapy with Y-90 ibritumomab tiuxetan (Zevalin) and gemicitabine in patients with non-hodgkin's lymphoma. Blood. 2007 Nov;110(11):192B-193B.
  • Bell DW, Kim SH, Godwin AK, Schiripo TA, Harris PL, Haserlat SM, Wahrer DC, Haiman CA, Daly MB, Niendorf KB, Smith MR, Sgroi DC, Garber JE, Olopade OI, Le Marchand L, Henderson BE, Altshuler D, Haber DA, Freedman ML. Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts. Int J Cancer. 2007 Dec;121(12):2661-7.
  • Bradley SV, Smith MR, Hyun TS, Lucas PC, Li L, Antonuk D, Joshi I, Jin F, Ross TS. Aberrant huntingtin interacting protein 1 in lymphoid malignancies. Cancer Res. 2007 Sep 15;67(18):8923-31.
  • Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MR. Cardiovascular mortality following androgen deprivation therapy in men with locally advanced prostate cancer: An analysis of RTOG 85-31. International Journal of Radiation Oncology Biology Physics. 2007;69(3):S170-S171.
  • Korde N, Smith M, Ward LD. Acute liver failure due to multiple myeloma infiltration. J Gen Intern Med. 2007 Apr;22:223.
  • Foss F, Sjak-Shie N, Goy A, Jacobsen E, Advani R, Smith M, Komrokji R, Pendergrass K, Bolejack V, Watts K, Acosta M. Denileukin diftitox (ONTAK) plus CHOP chemotherapy in patients with peripheral T-Cell lymphomas (PTCL), the Concept trial. Blood. 2007 Nov;110(11):1011A-1011A.
  • Chasky MC, Smith MR, Al-Saleem TI. Nasal NK/T cell lymphoma: Dramatic response to pegaspargase in two patients. Blood. 2007 Nov;110(11):187B-187B.
  • Smith MR, Jin F, Joshi I. Bortezomib Sensitizes Non Hodgkin's Lymphoma Cells to Apoptosis Induced by Antibodies to Tumor Necrosis Factor Related Apoptosis-Inducing Ligand (TRAIL) Receptors TRAIL-R1 and TRAIL-R2. Clin Cancer Res. 2007 Sep 15;13(18):5528s-34s.
  • Smith MR, Zhang L, Gordon LI, Foran J, Kahl B, Gascoyne RD, Advani R, Paietta E, Weller E, Horning SJ. Phase II study of R-CHOP followed by Y-90-ibritumomab tiuxetan in untreated mantle cell lymphoma: Eastern cooperative oncology group study E1499. Blood. 2007 Nov;110(11):121A-121A.
  • Wang HW, Cheng FD, Noyes D, Wright K, Mohapatra S, Tao J, Schell M, Sebti S, Smith M, Bhalla K, Pinilla J, Dessureault S, Celis D, Sotomayor EM. Enhancement the antigen-presenting cell function of mantle cell lymphomas (MCL) by novel molecularly based immunotherapeutic strategies. Blood. 2007 Nov;110(11):685A-685A.
Top

2006

  • Fayad L, Patel H, Verhoef G, Czuczman M, Foran J, Gine E, Rohatiner A, Smith MR, Shapiro M, Advani A. Clinical activity of the immunoconjugate CMC-544 in B-Cell malignancies: Preliminary report of the expanded maximum tolerated dose (MTD) cohort of a phase 1 study. Blood. 2006 Nov;108(11):766A-766A.
  • Borghaei H, Smith M, Millenson M, Shafer D, Thibodeau L, Schilder R. Phase I trial of combination therapy with Y-90 ibritumomab tiuxetan and gemcitabine in patients with non-Hodgkin is lymphoma. Blood. 2006 Nov;108(11):260B-260B.
  • Saville MW, Leonard JP, Hainsworth JD, Smith MR, Darif M, Park C, Schuster SJ. Role of different frontline regimens in achieving complete response in follicular lymphoma: A meta-analysis of CR rate a nd its relation to hazard rate for disease progression. Blood. 2006 Nov;108(11):779A-780A.
  • Joshi I, Jin F, Smith MR. Bortezomib sensitizes non-Hodgkin's lymphoma (NHL) cells to apoptosis induced by antibodies to trail receptors TRAIL-R1 and-R2. Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5528s-5534s..
  • Gitelson E, Al-Saleem T, Millenson M, Lessin S, Smith MR. Cutaneous B-cell lymphoma responds to rituximab: A report of five cases and a review of the literature. Leuk Lymphoma. 2006 Sep;47(9):1902-7.
  • Redfern CH, Guthrie TH, Bessudo A, Densmore JJ, Holman PR, Janakiraman N, Leonard JP, Levy RL, Just RG, Smith MR, Rosenfelt FP, Wiernik PH, Carter WD, Gold DP, Melink TJ, Gutheil JC, Bender JF. Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical response. J Clin Oncol. 2006 Jul 1;24(19):3107-12.
  • Smith MR, Chen H, Gordon L, Foran J, Kahl B, Advani R, Gascoyne RD, Weller E, Horning SJ. Phase II study of rituximab plus CHOP followed by Y-90-ibritumomab tiuxetan in patients with previously untreated mantle cell lymphoma: An Eastern Cooperative Oncology Group Study (E1499). J Clin Oncol. 2006 Jun;24(18):422S-422S.
  • Smith MR, Joshi I, Jin F, Al-Saleem T. Murine model for mantle cell lymphoma. Leukemia. 2006 May;20(5):891-3.
  • Smith MR, Joshi I, Jin F, Bradley SV, Ross TS. Role of Huntingtin interacting protein HIP-1 in Non-Hodgkin's lymphoma. Blood. 2006 Nov;108(11):675A-675A.
  • Narra K, Borghaei H, Al-Saleem T, Hoglund M, Smith MR. Pure red cell aplasia in B-cell lymphoproliferative disorder treated with rituximab: report of two cases and review of the literature. Leuk Res. 2006 Jan;30(1):109-14.
  • Roberts JD, Smith MR, Feldman EJ, Cragg L, Millenson MM, Roboz GJ, Honeycutt C, Thune R, Padavic-Shaller K, Carter WH, Ramakrishnan V, Murgo AJ, Grant S. Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (Non-Hodgkin's) lymphoma. Clin Cancer Res. 2006 Oct;12(19):5809-16.
Top

2005

  • Shafer D, Borghaei H, Millenson M, Nicolaou N, Al-Saleem TI, Leasure NC, Padavic K, Smith MR, Schilder RJ. Vinblastine, mitoxantrone and prednisone (MVP) followed by involved field radiotherapy (IF-XRT) for early clinical stage Hodgkins's lymphoma: Long term follow-up. Blood. 2005 2677 Part 1 Nov 16;106(11):751A-751A.
  • Younes A, Vose JM, Zelenetz AD, Smith MR, Burris H, Ansell S, Klein J, Kumm E, Czuczman M. Results of a phase 2 trial of HGS-ETR1 (Agonistic human monoclonal antibody to TRAIL receptor 1) in subjects with relapsed/refractory non-Hodgkin's lymphoma (NHL). Blood. 2005 489 Part 1 NOV 16;106(11):146A-147A.
  • Pro B, Smith MR, Leber B, Younes A, Fayad L, Hagemeister FB, McLaughlin P, Rodriguez AM, Caddick Y, Zwiebel JA. Phase II study of oblimersen sodium and rituximab in patients with recurrent B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2005 Part 1 Suppl. S JUN 1;23(16):587S-587S.
  • Schau HJ, Smith MF, Schau PI. The healthcare network economy: The role of Internet information transfer and implications for pricing. Industrial Marketing Management. 2005;34(2 SPEC. ISS.):147-56.
  • Briola C, Sweeney C, Holland J, Smith M, McGarvey J. A nursing retreat: A time to teach, strengthen, and renew the radiation oncology nurse. Oncol Nurs Forum. 2005 140 Mar;32(2):461.
  • Advani A, Gine E, Gisselbrecht C, Rohatiner A, Rosen S, Smith M, Boni J, Lejeune C, Patel H. Preliminary report of a phase 1 study of CMC-544, an antibody-targeted chemotherapy agent, in patients with B-Cell non-hodgkin's lymphoma (NHL). Blood. 2005 230 Part 1 NOV 16;106(11):71A-71A.
  • Smith M, Borghaei H. Comment on "Phase II study of weekly low-dose paclitaxel for relapsed and refractory non-Hodgkin's lymphoma: A Wisconsin Oncology Network Study,'' by Kahl et al., Cancer Investigation, 2005, 23(1), pp. 13-18. Cancer Invest. 2005;23 (6):572.
  • Narra K, Borghaei H, Al-Saleem T, Hoeglund M, Smith MR. Pure red cell aplasia in B-cell lymphoproliferative disorder treated with rituximab: Report of two cases and review of the literature. Leuk Res. 2005;30(1):109-14.
  • Smith MR, Joshi I, Jin F, Obasaju C. Enhanced efficacy of gemcitabine in combination with anti-CD20 monoclonal antibody against CD20+ non-Hodgkin's lymphoma cell lines in vitro and in scid mice. Bmc Cancer. 2005 No. 103 AUG 18;5:Art.
  • Smith MR, Joshi IJ, Jin F, Al-Saleem T. Development of B cell lymphoma in E-cyclin D1 X mutant p53 transgenic mice. Blood. 2005 1907 Part 1 NOV 16;106(11):541A-541A.
Top

2004

  • Borghaei H, Millenson M, Schilder R, Alden M, Rogatko A, Wang H, Padavic-Shaller K, Smith MR. Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma. Cancer (New York, NY, United States). 2004;101(9):2034-41.
  • Morris GJ, Millenson MM, Padavic-Shaller K, Wang H, Rogatko A, Clyde J, Boyd RL, Yeslow G, Halbherr T, Schilder RJ, Smith MR. Phase II study of fludarabine and alpha-interferon in patients with low-grade non-Hodgkin's lymphorna. Haematologica. 2004 Dec;89(12):1484-91.
  • Pro B, Smith MR, Younes A, Fayad LE, Goy AH, Hagemeister FB, McLaughlin P, Rodriguez MA, Frankel SR, Zwiebel JA, Anderson MD. Oblimersen sodium (Bcl-2 antisense) plus rituximab in patients with recurrent B-cell non-Hodgkin's lymphoma: Preliminary phase II results. J Clin Oncol. 2004 6572 Suppl. S Jul 15;22(14):575S-575S.
  • Arias-Mendoza F, Smith MR, Brown TR. Predicting treatment response in non-Hodgkin's lymphoma from the pretreatment tumor content of phosphoethanolamine plus phosphocholine. Acad Radiol. 2004 Apr;11(4):368-76.
  • Ibrahim D, Smith MR, Varterasian M, Karanes C, Millenson M, Yeslow G, Pemberton P, Lai P, Abrams J, Al-Katib A. Phase II study of PEND chemotherapy in patients with refractory/relapsed Hodgkin lymphoma. Leuk Lymphoma. 2004 Oct;45(10):2079-84.
  • Smith MR, Jin F, Joshi I. Enhanced efficacy of therapy with antisense BCL-2 oligonucleotides plus anti-CD20 monoclonal antibody in scid mouse/human lymphoma xenografts. Mol Cancer Ther. 2004 Dec;3(12):1693-9.
  • Smith MR, Jin F, Joshi I. Antibodies to TRAIL receptors TRAIL-R1 and R2 induce apoptosis in non-Hodgkin's lymphoma cells. Blood. 2004 3290 Part 1 Nov 16;104(11):899A-899A.
  • Smith MR, Jin F, Joshi I. Bortezomib sensitizes non-Hodgkin's lymphoma cells to apoptosis induced by antibodies to TRAIL receptors trail-R1 and R2. Blood. 2004 4614 Part 2 Nov 16;104(11):237B-237B.
Top

2003

  • Borghaei H, Mehta P, Millenson MM, Smith MR, Rogatko A, Al-Saleem T. Blood flow cytometric immunophenotyping can be predictive of bone marrow involvement in "low grade" and mantle cell lymphomas. Blood. 2003 Nov;102(11):281B-281B, Part 2.
  • Borghaei H, Millenson MM, Schilder RJ, Rogatko A, Alden M, Wang H, Padavic-Shaller KA, Minnitti C, Smith MR. Final results of the phase II trial of paclitaxel plus oral estramustine phosphate in patients with relapsed aggressive non-Hodgkin's Lymphoma. Blood. 2003 Nov;102(11):293B-293B, Part 2.
  • Wu H, Smith M, Millenson MM, Nicolaou N, Van Deerlin VM, Addya K, Lessin S, Al-Saleem T. Contribution of flow cytometry in the diagnosis of cutaneous lymphoid lesions. J Invest Dermatol. 2003 Dec;121(6):1522-30.
  • Cohen SD, Schilder RJ, Padavic-Shaller K, Entmacher MS, Rogatko A, Millenson MM, Smith MR. Dexamethasone and 13-cis-retinoic acid for untreated multiple myeloma. Blood. 2003 Nov;102(11):389B-390B, Part 2.
  • Haas NB, Smith M, Lewis N, Littman L, Yeslow G, Joshi ID, Murgo A, Bradley J, Gordon R, Wang H, Rogatko A, Hudes GR. Weekly bryostatin-1 in metastatic renal cell carcinoma: a phase II study. Clin Cancer Res. 2003 Jan;9(1):109-14.
  • Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003 Oct;22(47):7359-68.
Top

2002

  • Carroll PR, Kantoff PW, Balk SP, Brown MA, D'Amico A V, George DJ, Grossfeld GD, Johnson CS, Kelly WK, Klotz L, Lee WR, Lubeck DP, McLeod DG, Oh WK, Pollack A, Sartor O, Smith MR, Hart C. Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer. Urology. 2002 Sep;60(3 Suppl 1):1-6.
  • McGinnis KS, Shapiro M, Junkins-Hopkins JM, Smith M, Lessin SR, Vittorio CC, Rook AH. Denileukin diftitox for the treatment of panniculitic lymphoma. Arch Dermatol. 2002 Jun;138(6):740-2.
  • Franks SE, Smith MR, Arias-Mendoza F, Shaller C, Padavic-Shaller K, Kappler F, Zhang Y, Negendank WG, Brown TR. Phosphomonoester concentrations differ between chronic lymphocytic leukemia cells and normal human lymphocytes. Leuk Res. 2002 Oct;26(10):919-26.
  • Roberts JD, Smith MR, Feldman EJ, Cragg L, Grant S. Phase I study of bryostatin-1 and fludarabine in patients with chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma. Clin Lymphoma. 2002 Dec;3(3):184-8.
Top

2001

  • Joshi I, Jin F, Smith MR. Varying effector mechanisms of rituximab against human B cell lymphoma cells [meeting abstract]. Proceedings of the American Association for Cancer Research. 2001 2001;42:A4158.
  • DuHamel KN, Smith MY, Vickberg SM, Papadopoulos E, Ostroff J, Winkel G, Manne S, Redd WH. Trauma symptoms in bone marrow transplant survivors: The role of nonmedical life events. J Trauma Stress. 2001 Jan;14(1):95-113.
  • Smith MR, Joshi I, Jin F, Shields D, Renns J, Al-Saleem TA. Development of a murine model of mantle cell lymphoma. Blood. 2001;97:A3021.
  • Smith MR, Xie T, Zhou ZZ, Joshi I. Efficacy of treatment with antisense oligonucleotides complementary to immunoglobulin sequences of bcl-2/immunoglobulin fusion transcript in a t(14;18) human lymphoma-scid mouse model. Clin Cancer Res. 2001 Feb;7(2):400-6.
  • Khare L, Strizheva GD, Bailey JN, Au KS, Northrup H, Smith M, Smalley SL, Henske EP. A novel missense mutation in the GTPase activating protein homology region of TSC2 in two large families with tuberous sclerosis complex. J Med Genet. 2001 May;38(5):347-9.
Top

2000

  • Young NA, Ehya H, Klein-Szanto A, Litwin S, Smith MR, al-Saleem T. Differentiating large cell lymphoma from indolent small B-cell lymphoma in fine needle aspirates using p53, PCNA and transformed lymphocyte count. Acta Cytol. 2000 Jul-Aug;44(4):592-603.
  • Grant S, Cragg L, Smith M, Feldman E, Winning M, Roberts J, Tombes MB. Phase I trial of bryostatin 1 (NSC 339555) and F-ARA-AMP (fludarabine) in patients with progressive chronic lymphocytic leukemia (CLL) or refractory indolent non-Hodgkin's lymphoma. Blood. 2000 Nov 16;96(11):590.
  • Smith MR, Joshi I, Jin F. Combined therapy with antisense BCL-2 oligonucleotides (AS- BLC2-ODN) plus alpha CD20 monoclonal antibody in scid/human lymphoma xenografts. Blood. 2000 Nov 16;96(11):1458.
  • Smith MR, Xie T, Zhou ZZ, Joshi I. Antisense oligonucleotides complementary to immunoglobulin sequences of BCL-2/immunoglobulin fusion transcript induce apoptosis of t(14;18) lymphoma cells. Br J Haematol. 2000 Dec;111(4):1087-92.
Top